Respiratory syncytial virus vaccine - Biologic Drug Details

Summary for respiratory syncytial virus vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for respiratory syncytial virus vaccine

Recent Clinical Trials for respiratory syncytial virus vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Centre Hospitalier Annecy Genevois	PHASE3
Abogen Biosciences (Shanghai) Co., Ltd	PHASE2
Suzhou Abogen Biosciences Co., Ltd.	PHASE2

See all respiratory syncytial virus vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for respiratory syncytial virus vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for respiratory syncytial virus vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2034-07-24	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2036-08-18	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2035-09-16	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2034-11-25	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2035-03-02	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2036-01-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for respiratory syncytial virus vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2033-02-11	Patent claims search

International Patents for respiratory syncytial virus vaccine

Country	Patent Number	Estimated Expiration
Australia	2011252850
Canada	3078304
Guatemala	201700056
South Korea	102130584
Japan	2020040979
Canada	3035069

Market Dynamics and Financial Trajectory for Respiratory Syncytial Virus (RSV) Vaccines

Last updated: February 20, 2026

What are the current market drivers for RSV vaccines?

The global RSV vaccine market is primarily driven by the rising incidence of RSV-related hospitalizations and deaths among infants, elderly populations, and immunocompromised individuals. The increasing awareness and demand for preventative healthcare products also propel market growth.

Key factors include:

• Aging populations: The elderly, particularly those over 65, have high susceptibility to severe RSV infections.
• Pediatric infections: RSV is a leading cause of bronchiolitis and pneumonia among infants.
• Regulatory acceleration: The Food and Drug Administration (FDA) and European Medicines Agency (EMA) expedited review processes for RSV vaccines as of 2022.
• R&D investments: Rising investments by pharmaceutical companies in RSV vaccine development increase pipeline potential.

How does the pipeline affect market outlook?

Major pharmaceutical companies have multiple candidates in various clinical trial phases, indicating a robust pipeline. Leading contenders target maternal immunization, bolstering protection for infants, and adult vaccination strategies.

Pipeline specifics:	Company	Development Stage	Candidate Type	Target Population
Pfizer	Phase 3	Protein-based	Infants, elderly
GSK	Phase 3	Live-attenuated	Infants
Moderna	Phase 2	mRNA-based	Adults, elderly
Janssen	Phase 2	Protein-based	Elderly

What are the primary market challenges?

• Regulatory hurdles: Demonstrating efficacy across diverse populations remains complex.
• Pricing and reimbursement: High development costs translate into premium pricing, potentially limiting access.
• Manufacturing scalability: Producing vaccines at scale during a global pandemic or seasonal surges limits supply.
• Public acceptance: Vaccine hesitancy among parents and elderly populations could restrict uptake.

What are the projected financial trajectories?

The global RSV vaccine market is expected to expand significantly. Industry analysts forecast a compound annual growth rate (CAGR) of approximately 16-20% from 2022 to 2030.

Market size estimates:	Year	Market valuation (USD billion)	Notes
2022	2.2	Launch of first approved vaccines
2025	4.5	Increased adoption and approvals
2030	10.8	Full market penetration expected

Revenue streams are mainly from:

• Vaccine sales for infant, elderly, and maternal indications.
• Partnerships and licensing agreements.
• Government procurement programs.

How do competitive dynamics shape the market?

Market competition centers on vaccine efficacy, safety profiles, price, and regulatory timing. Key players include Pfizer, GSK, Moderna, and Janssen, with smaller biotech firms entering with novel platforms such as mRNA and vector-based vaccines.

Market share estimates:	Company	Estimated Market Share (2022)	Strategies
Pfizer	50%	Accelerated approval, broad portfolio
GSK	25%	Focus on pediatric formulations
Moderna	15%	Use of mRNA platform
Janssen	10%	Elderly-focused vaccines

What are the future market considerations?

• Expansion into low-income markets depends on pricing strategies and partnerships with global health organizations.
• Combination vaccines could counteract vaccine fatigue.
• Seasonality impacts manufacturing and distribution, requiring flexible supply chains.
• New delivery mechanisms like needle-free options may increase acceptance.

Key Takeaways

• The RSV vaccine market is expanding driven by aging populations, pediatric infections, and regulatory support.
• Multiple candidates in late-stage development indicate a high growth potential; pipeline diversity offers mitigated risk.
• Financial growth projected at a CAGR of 16-20% through 2030, reaching over USD 10 billion.
• Challenges include regulatory approval complexity, high R&D costs, manufacturing scale, and public trust.
• Competitive landscape favors those with strong pipelines, regulatory momentum, and strategic partnerships.

FAQs

1. When are RSV vaccines expected to reach global availability?
Most late-stage candidates anticipate approval between 2023 and 2024, with commercialization ramps continuing into the late 2020s.

2. Which demographic segments will benefit most from RSV vaccines?
Infants, elderly over 65, and immunocompromised individuals will see the most indirect and direct benefits.

3. What pricing strategies are companies employing?
Pricing aims to balance recoupment of R&D investments and access, often involving tiered pricing, especially in emerging markets.

4. How significant is the role of government funding in market growth?
Governments increasingly fund R&D and purchase agreements, especially as part of public health initiatives targeting vulnerable groups.

5. What are the key technological innovations?
mRNA and live-attenuated platforms are gaining prominence, offering potential advantages in efficacy and manufacturing scalability.

---

Sources:
[1] MarketWatch. (2022). RSV vaccine market size and growth forecast.
[2] FDA. (2022). RSV vaccine approval updates.
[3] EvaluatePharma. (2022). Biotech pipeline analysis.
[4] GlobalData. (2023). Immunization market outlook.
[5] World Health Organization. (2022). RSV burden and vaccine deployment strategies.